the mechanism by which the atypical antipsychotics (APs) improve psychosis with a "minimum" of extrapyramidal side effects (EPSEs) is thoughtprovoking (1) . Nevertheless, important observations remain unexplained. For example, according to this hypothesis, amoxapine should be atypical; however, it is not-at least, not in Parkinson's disease (PD) patients (2) . Pimozide, which is most similar clinically to haloperidol in terms of EPSEs, should in theory be more atypical than risperidone. Olanzapine, which certainly worsens parkinsonism in PD patients (thus illustrating its extrapyramidal effects), has very little effect on prolactin levels, in contrast to risperidone and the typicals. According to their D 2 binding, molindone and loxapine should be more atypical than risperidone, yet they seem to lack any special benefits other than those previously accorded to low-potency neuroleptics. Perhaps most intriguing is the observation that olanzapine treatment, which PD patients tolerate poorly owing to motor dysfunction, is virtually free from acute dystonic reactions-a property shared by quetiapine and clozapine, but not by risperidone.
Significant conflicting reports complicate efforts to interpret the EPSEs of these drugs, with studies reporting either major or no parkinsonism from olanzapine and risperidone (3). One study even reports that, when compared, neuroleptic-naïve young patients receiving equal dosages of either risperidone or haloperidol showed no differences in parkinsonism, acute dystonia, and akathisia (4).
While the "fast-off-D 2 " theory may be important, it does not completely explain the effects of the atypical APs, which all act on a myriad of neurotransmitters. The suggestion that thioridazine may be "relatively free" of EPSEs is speculative and, if true, not clearly related to its anticholinergic properties. There are clear limits to the benefits of anticholinergics in alleviating the signs and symptoms of neuroleptic-induced parkinsonism: concurrent treatment with anticholinergics reduces, but does not eliminate, parkinsonism. Conversely, clozapine's anticholinergic action is not mirrored in systemic side effects (for example, dry mouth, constipation, blurred vision, or impaired memory). Clozapine has potent antitremor effects in PD patients, and it works in patients who failed to respond to anticholinergics at higher dosages.
It is also apparent that formulating hypotheses is limited by conflicting data on just what motor side effects these drugs have.
I close by asking about the relevance of data suggesting preferential binding of drugs in and out of the striatum.
Joseph H Friedman, MD Pawtucket, Rhode Island

Reply: Atypical Antipsychotics Mechanisms of Action
Dear Editor:
The basic principle proposed in my article (1) is that there are 2 groups of antipsychotics (APs), those that bind tightly to the dopamine D 2 receptor and those that bind more loosely to the D 2 receptor (2) (3) (4) . The traditional APs, which elicit parkinsonism, bind to the dopamine D 2 receptor more tightly than does dopamine to the high-affinity state of the D 2 receptor. The newer, atypical APs, which elicit less or no parkinsonism, bind to the dopamine D 2 receptor more loosely than does dopamine to the highaffinity state of the D 2 receptor (1). APs that are more loosely bound to D 2 are able to come off the receptor more quickly, as found by human brain positron tomography with quetiapine and clozapine (4-7). This quality allows endogenous dopamine to conduct normal neurotransmission over a matter of hours.
A look at clozapine and isoclozapine, as well as loxapine and isoloxapine, supports this general principle of tightly bound and loosely bound types of APs and their relation to EPSEs. For example, clozapine and isoclozapine have identical affinities at the cloned muscarinic M 1 receptor, the dopamine D 1 and D 4 receptors, and the serotonin 1 A and 2 A receptors. However, isoclozapine has a tenfold higher affinity than clozapine for the human cloned D 2 receptor and correspondingly elicits catalepsy and hyperprolactinemia (7,8), in contrast to clozapine. Similarly, while loxapine and isoloxapine have similar affinities at the dopamine D 3 and D 4 receptors, and also at the 5-HT 1A and 5-HT 2A receptors, isoloxapine has a twofold-to-tenfold lower affinity for the D 2 receptor than does loxapine. As a result, isoloxapine does not lead to catalepsy or elevated prolactin (9), in contrast to loxapine.
Despite this basic underlying principle, however, there is no sharp clinical division between typical and atypical APs: dosage-dependent parkinsonism can occur with the moderately loosely bound APs such as olanzapine. Additional factors are to be considered for each of the The Canadian Journal of Psychiatry
